Francesco Marincola (Kite)
Gilead's Kite recruits an AbbVie/NIH veteran to head up cell therapy R&D. And he's taking aim at AML in a ferociously competitive field
Four months after Kite R&D exec Peter Emtage jumped ship to sign on with Versant as a CEO-in-waiting, the big Gilead sub has recruited …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
